Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Jun;141(6):1214-22.
doi: 10.1017/S095026881200194X. Epub 2012 Sep 7.

Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

H Aydemir  1 , D Akduman, N Piskin, F Comert, E Horuz, A Terzi, F Kokturk, T Ornek, G Celebi
Affiliations
Randomized Controlled Trial

Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia

H Aydemir et al. Epidemiol Infect. 2013 Jun.

Abstract

The aim of this study was to compare the responses of colistin treatment alone vs. a combination of colistin and rifampicin in the treatment of ventilator-associated pneumonia (VAP) caused by a carbapenem-resistant A. baumannii strain. Forty-three patients were randomly assigned to one of two treatment groups. Although clinical (P = 0·654), laboratory (P = 0·645), radiological (P = 0·290) and microbiological (P = 0·597) response rates were better in the combination group, these differences were not significant. However, time to microbiological clearance (3·1 ± 0·5 days, P = 0·029) was significantly shorter in the combination group. The VAP-related mortality rates were 63·6% (14/22) and 38·1% (8/21) for the colistin and the combination groups (P = 0·171), respectively. Our results suggest that the combination of colistin with rifampicin may improve clinical and microbiological outcomes of VAP patients infected with A. baumannii.

PubMed Disclaimer

References

    1. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical Microbiology Reviews 2008; 21: 538–582. - PMC - PubMed
    1. Garnacho-Montero J, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clinical Infectious Diseases 2003; 36: 1111–1118. - PubMed
    1. Olesen S, Madsen PO. Intravenous administration of sodium colistimethate in urinary tract infections. Current Therapeutic Research, Clinical and Experimental 1967; 9: 283–287. - PubMed
    1. Devlieger H, et al. Acute renal failure due to colistin intoxication. Acta Paediatrica Belgica 1977; 30: 179–181. - PubMed
    1. Tascini C, et al. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 1998; 42: 270–271. - PubMed

Publication types

MeSH terms